1. Day 1 ·
    EmergingDebate

    Sacituzumab tirumotecan lung data reframes ADC race

    Oncology commentary is debating how much weight to put on a progression-free-survival improvement from combining sacituzumab tirumotecan with pembrolizumab in advanced non-small cell lung cancer, given the endpoint's status relative to overall survival maturity in the same trial.

    The dominant readingA PFS win for this antibody-drug conjugate combination signals a real competitive threat to existing first-line NSCLC regimens.

    The pushbackPFS is a surrogate endpoint and the trial's overall-survival data remains immature, so the competitive positioning claim is premature.

    Cautiouslow volume→ stableThat day's page →

  2. Day 2 ·

    Nothing in it moved since the day before.

    EmergingDebate

    Sacituzumab tirumotecan lung data reframes ADC race

    Oncology commentary is debating how much weight to put on a progression-free-survival improvement from combining sacituzumab tirumotecan with pembrolizumab in advanced non-small cell lung cancer, given questions over the endpoint's maturity relative to overall survival data.

    The dominant readingSome oncology commentators argue the PFS improvement signals a meaningful new combination option in the crowded antibody-drug conjugate lung cancer race.

    The pushbackOthers caution that a PFS benefit without mature overall-survival data is a surrogate signal that has previously failed to translate into a genuine clinical outcome benefit in this class.

    Cautiouslow volume→ stableThat day's page →

Also running in Health

Every running conversation →The latest day →